Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Aug. 26, 2025 (HealthDay News) — For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial, ovarian, and meningioma cancers, according to a study published online Aug. 21 in JAMA Oncology<\/em>.<\/p>\n Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues compared the incidence of 14 cancers among adults with obesity prescribed GLP-1 RAs versus nonusers in a retrospective cohort study following a target trial emulation design using 2014 to 2024 electronic health record data from OneFlorida+. The study included adults eligible for antiobesity medications without prior cancer history: 43,317 GLP-1 RA users and 43,315 propensity score-matched nonusers.<\/p>\n The researchers found that the incidence rates of the 14 cancers were 13.6 and 16.4 per 1,000 person-years, respectively, with a significantly lower overall cancer risk among GLP-1 RA users versus nonusers (hazard ratio, 0.83). GLP-1 RA use was associated with a significantly reduced risk for endometrial cancer, ovarian cancer, and meningioma (hazard ratios, 0.75, 0.53 and 0.69, respectively) and with a marginally nonsignificant increased risk for kidney cancer.<\/p>\n “These findings highlight the importance of tailored risk assessments and underscore the need for further long-term studies to clarify the impact of GLP-1 RAs on cancer risk in high-risk populations,” the authors write.<\/p>\n One author disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n